Independent study published in clinical breast cancer shows activity of jaguar health's crofelemer for neratinib-induced diarrhea

A significant proportion of patients undergoing cancer therapy experience diarrhea, which has the potential to cause dehydration and non-adherence to cancer treatment regimens diarrhea was reported in 95% of neratinib-treated patients in randomized placebo-controlled trial san francisco, ca / accesswire / august 7, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or "the company") announced that the results of an independent pilot phase 2 study of crofelemer for the management of neratinib-associated diarrhea in patients with her2+ early-stage breast cancer indicate that crofelemer, the company's fda approved drug, may be effective for the management of neratinib-induced diarrhea. the results of the study, which was designed by the study's principal investigator, jo chien, md, and published in the peer-reviewed journal clinical breast cancer, are consistent with the results of a preclinical dog study evaluating the effects of crofelemer in improving diarrhea associated with neratinib, a tyrosine kinase inhibitor (tki), presented at the american association for cancer research virtual annual meeting ii in june 2020.
JAGX Ratings Summary
JAGX Quant Ranking